Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Oncolytics Bio (ONC.TO)

Oncolytics Bio (ONC.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 81,265
  • Shares Outstanding, K 57,634
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,304 K
  • 60-Month Beta 1.44
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.32
Trade ONC.TO with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.48
  • Most Recent Earnings -0.12 on N/A
  • Next Earnings Date 05/05/22
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.12
  • Number of Estimates 1
  • High Estimate -0.12
  • Low Estimate -0.12
  • Prior Year -0.13
  • Growth Rate Est. (year over year) +7.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.34 +0.75%
on 05/20/22
1.85 -27.03%
on 05/05/22
-0.46 (-25.41%)
since 04/20/22
3-Month
1.34 +0.75%
on 05/20/22
2.22 -39.19%
on 02/22/22
-0.87 (-39.19%)
since 02/18/22
52-Week
1.34 +0.75%
on 05/20/22
3.87 -65.12%
on 06/01/21
-2.33 (-63.32%)
since 05/20/21

Most Recent Stories

More News
Stocks in play: Oncolytics Biotech Inc

Today announced that Dr. Matt Coffey, President and Chief Executive Officer, will participate in a fireside ...

ONC.TO : 1.35 (-4.26%)
New Approaches Towards Immunotherapy Give Hope in Fight Against Solid Tumors

VANCOUVER – USA News Group – Hope is on the horizon for revolutionary treatments meant to target solid tumors, which have historically been some the toughest cancers to treat. Beyond extending life...

ONCY : 1.0700 (-1.83%)
ONC.TO : 1.35 (-4.26%)
GILD : 63.84 (+0.90%)
BNTX : 163.00 (-2.90%)
NVS : 89.42 (+0.87%)
BMY : 76.19 (+0.30%)
Stocks in play: Oncolytics Biotech Inc

Today announced new clinical biomarker data demonstrating pelareorep's immunotherapeutic effects, synergy ...

ONC.TO : 1.35 (-4.26%)
HER2-Targeted Therapies Introduced Early in Breast Cancer Treatment Offering Hope for Patients

Palm Beach, FL – May 4, 2022 – FinancialNewsMedia.com News Commentary – Globally, the R&D on breast cancer in all its forms has been steadily growing at a significant pace over the last several years...

ONCY : 1.0700 (-1.83%)
ONC.TO : 1.35 (-4.26%)
BLTE : 12.68 (+1.77%)
ENDP : 0.4650 (-19.52%)
CLVS : 0.7130 (-0.04%)
PFE : 52.47 (+3.59%)
Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep’s Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting

Pelareorep treatment resulted in a favorable Risk of Recurrence Score (ROR-S) in 100% of evaluable patients compared to 55% at baseline in a window-of-opportunity study    Statistically significant increases...

ONCY : 1.0700 (-1.83%)
ONC.TO : 1.35 (-4.26%)
Stocks in play: Oncolytics Biotech Inc

Today announced the acceptance of an abstract for a poster presentation at the upcoming European Society ...

ONC.TO : 1.35 (-4.26%)
Stocks in play: Oncolytics Biotech Inc

Announced that it will host a conference call and webcast on Thursday, May 5, 2022, at 5:00 p.m. ET ...

ONC.TO : 1.35 (-4.26%)
New Developments in Solid Tumor Therapeutics Continue to Give Hope to Patients

USA News Group – Hope is on the horizon for revolutionary treatments meant to target solid tumors, which have historically been some the toughest cancers to treat. Beyond extending life expectancy, the...

ONCY : 1.0700 (-1.83%)
ONC.TO : 1.35 (-4.26%)
GILD : 63.84 (+0.90%)
BNTX : 163.00 (-2.90%)
NVS : 89.42 (+0.87%)
BMY : 76.19 (+0.30%)
Stocks in play: Oncolytics Biotech Inc

Announced they will be presenting a corporate overview at the Bloom Burton & Co. Healthcare Investor ...

ONC.TO : 1.35 (-4.26%)
Stocks in play: Oncolytics Biotech Inc

Today announced the publication of preclinical data demonstrating the synergistic anti-cancer activity ...

ONC.TO : 1.35 (-4.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Key Turning Points

3rd Resistance Point 1.49
2nd Resistance Point 1.47
1st Resistance Point 1.44
Last Price 1.35
1st Support Level 1.39
2nd Support Level 1.37
3rd Support Level 1.34

See More

52-Week High 3.87
Fibonacci 61.8% 2.90
Fibonacci 50% 2.61
Fibonacci 38.2% 2.31
Last Price 1.35
52-Week Low 1.34

See More

Business Summary

Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar